Who Is Marvin S. Hausman? Co-Founder and Chief Scientific Officer of Xycota
A profile of Xycota Co-Founder and Chief Scientific Officer Marvin S. Hausman, M.D.
Marvin S. Hausman, M.D., is the Co-Founder and Chief Scientific Officer of Xycota, leading Xycota Biosciences, LLC alongside Brad Listermann FinanzNachrichten.de.
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
Hausman brings over 50 years of central nervous system (CNS) drug development experience, has achieved 6 successful FDA New Drug Applications (NDAs), and has a track record of commercial exits StreetInsider.com.
Where Marvin S. Hausman Is Now
- Current role: Co-Founder and Chief Scientific Officer
- Organization: Xycota (Xycota Biosciences, LLC)
- Known for: Over 50 years of CNS drug development experience and research into low-dose psilocybin
- Recent news: Under a proposed acquisition agreement with BioAdaptives, Inc., Xycota was structured to continue under its executive and scientific leadership, including Hausman
Marvin S. Hausman, M.D., serves as Co-Founder and Chief Scientific Officer of Xycota, where he leads Xycota Biosciences, LLC with Brad Listermann FinanzNachrichten.de.
Career and Drug Development Track Record
Hausman is a medical doctor (M.D.) who has accumulated over 50 years of CNS drug development experience StreetInsider.com.
Across his career, he has achieved 6 successful FDA New Drug Applications (NDAs) and established a track record of commercial exits StreetInsider.com.
Psilocybin Research and Neuroplasticity
Hausman co-authored a 2026 study published in Neuropsychopharmacology titled 'Psilocybin improves novel object recognition... through the modulation of the BDNF/TrkB signaling pathway' StreetInsider.com. The research demonstrated that repeated low-dose psilocybin improved recognition memory in a rat model of Fragile X syndrome FinanzNachrichten.de.
Hausman has stated that if clinical studies support the ability of a low, sub-perceptual dose of psilocybin or psilocin to engage the BDNF/TrkB pathway involved in neuroplasticity without hallucinogenic effects, it could open a path toward a PTSD treatment that fits into patients' daily lives FinanzNachrichten.de.
Recent Corporate Agreements
Under a proposed acquisition agreement with BioAdaptives, Inc., Xycota was structured to continue operating under its executive and scientific leadership, including Hausman FinanzNachrichten.de.
The transaction agreement between BioAdaptives and Xycota also specified that Xycota founders, including Hausman and their affiliates, would receive no interest in a possible nutraceutical spin-off entity FinanzNachrichten.de.
Frequently asked questions
Who is Marvin S. Hausman?
Marvin S. Hausman, M.D., is the Co-Founder and Chief Scientific Officer of Xycota, where he leads Xycota Biosciences, LLC alongside Brad Listermann FinanzNachrichten.de.
What is Marvin S. Hausman's background in drug development?
Hausman is a medical doctor with over 50 years of CNS drug development experience, 6 successful FDA New Drug Applications (NDAs), and a history of commercial exits StreetInsider.com.
What scientific research has Marvin S. Hausman co-authored on psilocybin?
Hausman co-authored a 2026 study in Neuropsychopharmacology titled 'Psilocybin improves novel object recognition... through the modulation of the BDNF/TrkB signaling pathway', which showed that repeated low-dose psilocybin improved recognition memory in a rat model of Fragile X syndrome FinanzNachrichten.de StreetInsider.com.
What has Marvin S. Hausman stated regarding low-dose psilocybin and PTSD?
Hausman stated that if clinical studies support using low, sub-perceptual doses of psilocybin or psilocin to engage the BDNF/TrkB pathway involved in neuroplasticity without hallucinogenic effects, it could open a path toward a PTSD treatment that fits into patients' daily lives FinanzNachrichten.de.
What terms applied to Marvin S. Hausman in the BioAdaptives transaction agreement?
Under the proposed acquisition agreement with BioAdaptives, Inc., Xycota was structured to continue under its executive and scientific leadership, including Hausman, while Hausman and other founders would receive no interest in a possible nutraceutical spin-off entity FinanzNachrichten.de.
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Marvin S. Hausman or Xycota Biosciences. See more people in psychedelic medicine.